Rivaroxaban Dose for PAD with eGFR 36.5 mL/min/1.73 m²
Use rivaroxaban 2.5 mg twice daily plus aspirin 75-100 mg once daily in this patient with PAD and eGFR 36.5 mL/min/1.73 m², as no dose adjustment is required for renal function in the vascular protection indication.
Dosing Algorithm
The appropriate rivaroxaban regimen depends on:
- Renal function threshold: eGFR 36.5 mL/min/1.73 m² is above the critical cutoff
- Bleeding risk assessment: Must exclude high-risk bleeding features
- Ischemic risk stratification: PAD qualifies as high ischemic risk
Specific Dose Recommendation
Rivaroxaban 2.5 mg twice daily + aspirin 75-100 mg once daily is the evidence-based regimen 1, 2, 3.
Key Renal Considerations
- No dose adjustment needed: The FDA label explicitly states "No dose adjustment needed based on CrCl" for the vascular protection indication in PAD 3
- Safety threshold: This regimen is appropriate for eGFR ≥15 mL/min 3
- Your patient's eGFR of 36.5: Well above the safety threshold and requires standard dosing
The 2024 ESC guidelines recommend this combination "for patients with PAD and high ischaemic risk, and non-high bleeding risk" 1. The 2024 ACC/AHA guidelines similarly support this regimen, noting it reduces both major adverse cardiovascular events (MACE) and major adverse limb events (MALE) 2.
Critical Bleeding Risk Exclusions
Do NOT use rivaroxaban 2.5 mg if the patient has:
- Active bleeding or bleeding within the past 3 months
- Dual antiplatelet therapy requirement
- Active gastroduodenal ulcer
- History of hemorrhagic or lacunar stroke
- Severe thrombocytopenia
- Recent intracranial bleeding
The MAGELLAN study specifically excluded patients with these high bleeding risk features, and they experienced excess bleeding with rivaroxaban 3.
Timing After Revascularization
If this patient recently underwent lower extremity revascularization:
- Initiate once hemostasis is established 3
- The VOYAGER-PAD trial demonstrated particular benefit in post-revascularization patients, with a 73% relative risk reduction in the primary endpoint for those with prior revascularization history 4
Evidence Strength
The COMPASS trial (27,395 patients) provides the foundational evidence, demonstrating:
- 24% reduction in MACE (HR 0.76,95% CI 0.66-0.86, p<0.00004) 3
- Benefit observed early with constant treatment effect over 23 months 3
- Favorable benefit-risk: 70 fewer CV events per 10,000 patient-years versus 12 additional life-threatening bleeds 3
For PAD specifically, rivaroxaban 2.5 mg plus aspirin reduces acute limb ischemia by 35% (RR 0.65,95% CI 0.55-0.78) 5.
Monitoring Requirements
- Assess bleeding risk at baseline and periodically 6
- Monitor adherence: Real-world data shows only 43% of patients remain adherent, but those who do achieve 70% lower amputation rates 7
- Annual follow-up minimum to assess clinical status and medication adherence 1
Common Pitfall
Do not confuse this with the 10 mg or 15 mg doses used for VTE treatment or prophylaxis. The vascular protection dose is specifically 2.5 mg twice daily - this lower dose targets the coagulation pathway's contribution to atherothrombosis while minimizing bleeding risk 8, 9.